Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2020-10-15 Earnings Release
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2020
Earnings Release Classification · 1% confidence The document is titled "THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2020" (Theranexus Publishes its Cash Position as of September 30, 2020). It explicitly states the cash position (€11.9 M) as of a specific date (September 30, 2020) and compares it to the previous period (June 30, 2020). This content is characteristic of a periodic financial update focusing on liquidity, which aligns best with an Interim/Quarterly Report (IR) or an Earnings Release (ER). Since it focuses specifically on the cash position and operational outlook rather than comprehensive financial statements (which would suggest IR) or just key highlights (ER), and given the short length (2904 chars) and the nature of the announcement (a specific financial metric update), it functions as a focused financial update. In the context of the provided definitions, this is a concise report on a specific financial metric for a period shorter than a year, making 'Interim / Quarterly Report' (IR) the most appropriate fit, although 'Earnings Release' (ER) is also plausible if this is the primary release for the quarter. Given the focus on 'trésorerie' (cash position) and operational updates for the next quarter, it leans towards an Earnings Release (ER) which typically precedes or is the initial announcement of quarterly results. 9M 2020
2020-10-15 French
THERANEXUS ANNOUNCES ITS FIRST HALF 2020 RESULTS
Earnings Release Classification · 1% confidence The document is a press release titled 'THERANEXUS ANNOUNCES ITS FIRST HALF 2020 RESULTS'. It provides a summary of financial highlights, including a table comparing H1-2020 and H1-2019 figures, and discusses operational updates and clinical program progress. It explicitly states that the full half-year report will be available on a later date. Since this is an initial announcement of financial results rather than the full interim report itself, it is classified as an Earnings Release. H1 2020
2020-09-29 English
RESULTATS DU PREMIER SEMESTRE 2020
Earnings Release Classification · 1% confidence The document is a press release titled 'THERANEXUS ANNONCE SES RESULTATS DU PREMIER SEMESTRE'. It provides a summary of financial results for the first half of 2020, including a table of financial data, and discusses business updates and clinical program progress. It explicitly states that the full 'Rapport Semestriel' (Interim Report) will be available on a later date. Since this document provides the initial announcement of financial results with key highlights rather than the full comprehensive report, it is classified as an Earnings Release (ER). H1 2020
2020-09-29 French
THERANEXUS PRESENTS ITS LATEST SCIENTIFIC NEWS
Regulatory Filings Classification · 1% confidence The document is a press release dated September 9, 2020, announcing scientific news, including a new research partnership, several new scientific publications, and participation/presentation at the European Congress of Neuropsychopharmacology (ECNP). This type of announcement, detailing scientific progress, partnerships, and upcoming conference presentations, is characteristic of general corporate updates aimed at investors and the scientific community, but it does not fit neatly into the specific financial filing categories like 10-K, ER, or IR. It is not a formal regulatory filing (RNS) in the sense of mandatory disclosure, nor is it a formal Investor Presentation (IP) or Earnings Release (ER). Given the content focuses on scientific milestones and general corporate updates rather than specific financial results or mandatory governance disclosures, the most appropriate category is the general Regulatory Filings/Announcements fallback, RNS, as it serves as a broad communication to the market about company activities.
2020-09-09 English
THERANEXUS FAIT LE POINT SUR SON ACTUALITÉ SCIENTIFIQUE
Regulatory Filings Classification · 1% confidence The document is a press release dated September 9, 2020, detailing scientific updates, new research collaborations (with Université de Lyon/CERMEP), recent scientific publications (in Frontiers in Neuroscience, Neuropharmacology, SLAS Discovery, Therapies), and participation in an upcoming scientific congress (ECNP). It announces scientific progress and corporate activities rather than releasing periodic financial results (ER/IR) or providing official statutory reports (10-K/AR). Since it is an announcement detailing corporate and scientific news that doesn't fit the specific categories like ER, IR, or M&A, it falls best under the general Regulatory Filings category (RNS) as a corporate news release, although it heavily leans towards Investor Relations content. Given the options, RNS is the most appropriate catch-all for non-financial, non-statutory corporate news announcements.
2020-09-09 French
INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL
Share Issue/Capital Change Classification · 1% confidence The document is titled 'INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL' (Information relative to the total number of voting rights and shares comprising the share capital) and explicitly states the number of shares and total theoretical voting rights as of August 31, 2020, referencing French commercial code articles (L. 233-8 II du code de commerce et 223-16 du règlement général de l'AMF). This type of mandatory periodic disclosure regarding the total share capital and voting rights structure is typically classified as a regulatory filing or a specific capital structure update. Given the options, it most closely relates to a notification about the capital structure, which aligns best with 'Share Issue/Capital Change' (SHA) or a general 'Regulatory Filing' (RNS). Since it is a specific, mandatory disclosure about the total number of shares and voting rights, it is a direct notification about the capital structure. However, none of the codes perfectly match a 'Total Share Capital Disclosure'. Comparing the definitions, 'SHA' (Share Issue/Capital Change) is the closest fit as it deals with the composition of the capital, even if it's a periodic update rather than a new issuance. If it were purely a notification of a change in a major shareholder, it would be MRQ. Since it is the total count, SHA is plausible, but RNS (Regulatory Filings - fallback) is often used for mandatory disclosures that don't fit elsewhere. Given the content is a direct, periodic statement of the capital structure, and not a dividend (DIV) or director dealing (DIRS), I will classify it as a general regulatory filing (RNS) as it is a standard compliance announcement that doesn't fit the more specific capital action codes like SHA (which usually implies an issuance/buyback event) or MRQ (major shareholder change). The document is short and is a direct announcement, not an attachment, so RPA is not applicable.
2020-09-07 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.